USANA Health Sciences Inc (USNA)
Official siteCONSUMER DEFENSIVE • PACKAGED FOODS • NYSE
Market Cap: $244.79M
Last updated: Nov 17, 2026 at 11:06 AM ET
USANA Health Sciences Inc (USNA) Financials: Revenue, Profit and Cash Flow
USANA Health Sciences reported revenue of $925.26M for the fiscal year ended Dec 31, 2025, up 8.3% from the year before. That year, net income was $10.76M with a net margin of 1.2%, operating cash flow was $22.35M and free cash flow was $8.53M. The quarter ended Sep 30, 2026 had revenue of $205.88M and net income of -$5.56M.
Revenue and Margins
The operating margin was 5.5% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $1.01B, a compound annual decline of 1.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $925.26M | +8.3% | 78.3% | 5.5% | 1.2% |
| Dec 2024 | $854.50M | -7.2% | 79.4% | 7.8% | 4.9% |
| Dec 2023 | $921.01M | -7.8% | 79.4% | 10.1% | 6.9% |
| Dec 2022 | $998.60M | -15.8% | 80.6% | 10.8% | 6.9% |
| Dec 2021 | $1.19B | +4.6% | 81.6% | 14.3% | 9.8% |
| Dec 2020 | $1.13B | +7.0% | 81.6% | 15.6% | 11.0% |
| Dec 2019 | $1.06B | -10.8% | 82.3% | 13.8% | 9.5% |
| Dec 2018 | $1.19B | +13.6% | 83.1% | 15.8% | 10.6% |
| Dec 2017 | $1.05B | +4.1% | 82.9% | 12.7% | 6.0% |
| Dec 2016 | $1.01B | N/A | 82.1% | 13.8% | 9.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 74.4% from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $925.26M | $854.50M | $921.01M | $998.60M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B |
| Cost of revenue | $200.85M | $175.75M | $189.40M | $193.89M | $217.90M | $209.11M | $187.50M | $200.71M | $179.40M | $180.19M |
| Gross profit | $724.40M | $678.75M | $731.62M | $804.71M | $968.57M | $925.53M | $873.40M | $988.54M | $867.86M | $825.89M |
| Research and development | $0 | $11.57M | $11.45M | $11.56M | $11.11M | $10.63M | $10.26M | $8.84M | $8.95M | $8.84M |
| Operating income | $50.86M | $66.32M | $93.07M | $107.61M | $170.19M | $176.49M | $146.19M | $188.35M | $132.50M | $138.62M |
| Net income | $10.76M | $42.03M | $63.79M | $69.35M | $116.50M | $124.66M | $100.53M | $126.22M | $62.53M | $100.04M |
| EBITDA | $82.07M | $98.86M | $123.11M | $129.02M | $192.38M | $199.00M | $169.20M | $205.20M | $148.61M | $152.10M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $205.88M | $223.27M | $250.22M | $226.20M | $213.67M | $235.85M | $249.54M | $213.61M | $200.22M | $212.87M | $227.80M | $221.08M |
| Gross profit | $157.17M | $174.93M | $190.78M | $176.79M | $164.85M | $177.92M | $188.75M | $171.06M | $157.40M | $168.72M | $181.57M | $175.85M |
| Operating income | -$1.45M | -$20.00M | $13.87M | $17.25M | $1.22M | $16.72M | $15.67M | $8.21M | $15.60M | $17.84M | $24.67M | $24.22M |
| Net income | -$5.56M | -$21.38M | $7.51M | -$1.77M | -$6.52M | $9.65M | $9.40M | $4.48M | $10.61M | $10.43M | $16.54M | $16.77M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $14.00M by $144.38M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $742.91M | $748.19M | $632.76M | $596.55M | $577.74M | $640.89M | $516.93M | $554.46M | $519.27M | $470.64M |
| Current assets | $288.40M | $279.19M | $417.75M | $381.23M | $362.85M | $423.21M | $327.61M | $392.33M | $340.16M | $277.86M |
| Cash and equivalents | $158.38M | $181.77M | $330.42M | $288.42M | $239.83M | $312.88M | $234.83M | $214.33M | $247.13M | $175.77M |
| Total liabilities | $156.64M | $161.86M | $135.56M | $162.08M | $182.62M | $199.24M | $165.22M | $163.32M | $156.06M | $145.35M |
| Short-term debt | $14.00M | $29.01M | $8.06M | $6.89M | $7.08M | $8.62M | $8.32M | $20.77M | $17.00M | $21.46M |
| Shareholder equity | $533.10M | $532.11M | $497.20M | $434.47M | $395.12M | $441.65M | $351.71M | $391.15M | $363.21M | $325.29M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $708.47M | $703.21M | $738.97M | $742.91M | $726.59M | $734.53M | $746.60M | $748.19M | $671.31M | $631.42M | $629.27M | $632.76M |
| Total liabilities | $138.38M | $132.24M | $144.18M | $156.64M | $145.04M | $148.97M | $162.72M | $161.86M | $138.22M | $119.21M | $129.29M | $135.56M |
| Cash and equivalents | $178.91M | $168.56M | $162.75M | $158.38M | $145.35M | $151.34M | $179.61M | $181.77M | $364.89M | $332.42M | $328.34M | $330.42M |
| Shareholder equity | $526.76M | $526.31M | $543.55M | $533.10M | $528.07M | $531.06M | $529.76M | $532.11M | $533.09M | $512.21M | $499.99M | $497.20M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 38.2% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $22.35M | $60.99M | $70.64M | $103.90M | $121.23M | $160.40M | $126.73M | $152.12M | $123.78M | $137.03M |
| Capital expenditures | $13.82M | $10.07M | $14.49M | $10.40M | $12.76M | $15.09M | $16.57M | $11.43M | $13.22M | $32.70M |
| Free cash flow | $8.53M | $50.92M | $56.15M | $93.50M | $108.46M | $145.31M | $110.16M | $140.69M | $110.56M | $104.33M |
| Investing cash flow | -$10.13M | -$213.09M | -$11.97M | -$12.37M | -$14.19M | -$33.96M | $47.49M | -$69.00M | -$12.90M | -$31.88M |
| Financing cash flow | -$40.60M | $9.55M | -$14.24M | -$30.09M | -$181.41M | -$59.44M | -$152.05M | -$105.28M | -$50.32M | -$64.86M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.96M | $23.32M | $9.76M | -$3.39M | -$1.96M | $12.22M | $15.48M | $5.79M | $29.53M | $7.99M | $17.68M | $26.02M |
| Capital expenditures | $3.52M | $3.15M | $2.65M | $2.79M | $3.20M | $5.03M | $2.80M | $1.80M | $2.40M | $2.67M | $3.20M | $7.32M |
| Free cash flow | $8.44M | $20.16M | $7.11M | -$6.18M | -$5.16M | $7.19M | $12.68M | $3.98M | $27.14M | $5.32M | $14.48M | $18.70M |
Frequently Asked Questions About USNA
What is USANA Health Sciences' annual revenue?
USANA Health Sciences reported revenue of $925.26M for the fiscal year ended Dec 31, 2025.
How fast is USANA Health Sciences' revenue growing?
Revenue was up 8.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.5%.
Is USANA Health Sciences profitable?
Yes. USANA Health Sciences reported net income of $10.76M for the fiscal year ended Dec 31, 2025, with a net margin of 1.2%.
How much free cash flow does USNA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $22.35M minus capital expenditures of $13.82M produced free cash flow of $8.53M.
How much debt does USANA Health Sciences have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $14.00M and cash and equivalents of $158.38M.
USNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors